Score Overview
Explore the 2021 public Archive ranking →
Where Rigel Pharmaceuticals Inc has ranked, year by year
Showing 5 years ranking history by HDB Score.
Has not reached the top 50 on HDB Score in any year we have ranked.
- RIGL
2006: 92.3% · 2021: 48.3% · free through 2021 · longest runs
Net Income x Stock Price
Historical Returns
| Period | Price | Return |
|---|---|---|
Last Price2026-09-29 | $ 48.89 | — |
1 Year2025-09-29 | $ 28.75 | 70.05% |
5 Years2021-09-29 | $ 36.30 | 34.68% |
10 Years2016-09-29 | $ 35.70 | 36.95% |
20 Years2006-09-29 | $ 102.70 | -52.40% |
All Time2000-11-29 | $ 639.84 | -92.36% |
| Period | Last Price2026-09-29 | 1 Year2025-09-29 | 5 Years2021-09-29 | 10 Years2016-09-29 | 20 Years2006-09-29 | All Time2000-11-29 |
|---|---|---|---|---|---|---|
| Price | $ 48.89 | $ 28.75 | $ 36.30 | $ 35.70 | $ 102.70 | $ 639.84 |
| Return | — | 70.05% | 34.68% | 36.95% | -52.40% | -92.36% |
Prices are split & dividend adjusted. All values are reported in USD.
Fundamental Data
Reported in USD
| Year | |||
|---|---|---|---|
| TTM | $ 276M | $ 321M | $ 95M |
| 2025 | $ 294M | $ 367M | $ 154M |
| 2024 | $ 179M | $ 17M | $ 77M |
| 2023 | $ 116M | -$ 25M | $ 56M |
| 2022 | $ 120M | -$ 58M | $ 58M |
| 2021 | $ 149M | -$ 17M | $ 124M |
| 2020 | $ 108M | -$ 29M | $ 57M |
| 2019 | $ 59M | -$ 66M | $ 98M |
| 2018 | $ 44M | -$ 70M | $ 128M |
| 2017 | $ 4M | -$ 77M | $ 115M |
| 2016 | $ 20M | -$ 69M | $ 74M |
| 2015 | $ 28M | -$ 51M | $ 126M |
| 2014 | $ 8M | -$ 90M | $ 143M |
| 2013 | $ 7M | -$ 89M | $ 211M |
| 2012 | $ 2M | -$ 98M | $ 298M |
| 2011 | $ 4M | -$ 85M | $ 247M |
| 2010 | $ 125M | $ 37M | $ 177M |
| 2009 | $ 750K | -$ 111M | $ 133M |
| 2008 | -$ 132M | $ 134M | |
| 2007 | $ 12M | -$ 74M | $ 108M |
| 2006 | $ 33M | -$ 37M | $ 104M |
| 2005 | $ 16M | -$ 45M | $ 138M |
| 2004 | $ 4M | -$ 56M | $ 71M |
| 2003 | $ 11M | -$ 41M | $ 46M |
| 2002 | $ 15M | -$ 37M | $ 27M |
| 2001 | $ 15M | -$ 23M | $ 33M |
| IPO2000 | $ 13M | -$ 25M | $ 52M |
Rigel Pharmaceuticals Inc fundamental performance
Between 2020 and 2025, revenue grew from $ 108M to $ 294M and net income went from -$ 29M to $ 367M. Revenue increased in 2 of those 5 years; net income in 3.
Between 2015 and 2025, revenue grew from $ 28M to $ 294M and net income went from -$ 51M to $ 367M. Revenue increased in 6 of those 10 years; net income in 7.
Rigel Pharmaceuticals Inc currently holds a 20-year HDB Score of 4.7 out of 10. How the HDB Score is calculated.
Membership
Continue RIGL’s history
The public Archive runs through 2021. Membership adds recent and current rankings.
- Recent and current rankings across 3,814 companies
- Compare companies with the latest data
- Track your research shortlist in a portfolio
